[Evaluation of the anti-emetic effectiveness of two drug formulations of Ondansetron in combined chemotherapy for children with malignant tumors]. / Otsenka antiémetogennoi éffektivnosti dvukh lekarstvennykh form ondansetrona pri kombinirovannoi khimioterapii zlokachestvennykh opukholei u detei.
Vopr Onkol
; 45(4): 424-8, 1999.
Article
em Ru
| MEDLINE
| ID: mdl-10532104
ABSTRACT
A double-blind randomized comparison (protocol S3AB4003, Glaxo Wellcome, Great Britain) carried out in a group of 52 children showed that the 5-HT3-receptor antagonist ondansetron (in syrup) effectively prevented vomiting, nausea and loss of appetite caused in combination chemotherapy with highly- or moderately emetogenic cytostatic drugs in 92.3; 69.3 and 81.0%, respectively. Treatment was given to patients who were on dexamethasone. With intravenous injection of ondansetron plus dexamethasone, per os, said indices were 88.5; 73.2%; 73.2%, respectively, thus showing no significant differences. No side-effects were observed with either regimen.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antagonistas da Serotonina
/
Vômito
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Ondansetron
/
Antieméticos
/
Náusea
/
Neoplasias
Tipo de estudo:
Clinical_trials
/
Guideline
Limite:
Child
/
Child, preschool
/
Humans
Idioma:
Ru
Ano de publicação:
1999
Tipo de documento:
Article